Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Subsequent Events (Details)

v3.8.0.1
Subsequent Events (Details) - Subsequent Event [member] - USD ($)
Mar. 13, 2018
Jan. 25, 2018
Jan. 08, 2018
Mar. 09, 2018
Statement Line Items [Line Items]        
Aggregate ordinary shares 3,333,336      
Warrants to purchase shares 2,500,002      
Aggregate purchase price $ 5,000      
Total upfront and milestone payment   $ 2,200,000    
Warrants issued       982,344
Warrants term The warrants may be exercised after 6 months from the date of issuance for a period of five and a half years.      
Placement agent warrants [Member]        
Statement Line Items [Line Items]        
Warrants to purchase shares 166,667      
ADS [Member]        
Statement Line Items [Line Items]        
Aggregate ordinary shares 6,666,672      
Warrants to purchase shares 5,000,004      
Warrant exercise price $ 2.00      
ADS [Member] | Placement agent warrants [Member]        
Statement Line Items [Line Items]        
Warrants to purchase shares 333,334      
Warrant exercise price $ 2.00      
Gebro Holding [member]        
Statement Line Items [Line Items]        
Sale of milestone description     (i) €300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and €300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between €750 thousand and €1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between €300 thousand and up to €4,025 thousand upon meeting certain net sales.  
Gebro Holding [member] | Euro [Member]        
Statement Line Items [Line Items]        
Total upfront and milestone payment     $ 1,500,000  
March 2014 Financing [Member]        
Statement Line Items [Line Items]        
Warrants issued       98,234